Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cannabis use may alter psychosis severity in methamphetamine users

NCT ID NCT07459270

Knowledge-focused Sponsor: Elazığ Mental Health and Diseases Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 2 times

Summary

This study will follow 90 people hospitalized with methamphetamine-induced psychotic disorder, comparing those who have also used cannabis in their lifetime to those who have not. Researchers will assess psychiatric symptoms, insight, addiction severity, and sleep quality weekly for eight weeks. The goal is to see if cannabis use influences the severity and course of psychosis, and to identify other factors that may play a role.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors understand how cannabis use changes the course of methamphetamine-induced psychosis, leading to better treatment approaches.
What could go wrong
This is an observational study that has not yet started recruiting. It only looks at factors, not a treatment, so it cannot directly improve outcomes. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of adult male participants aged 18-65 years who were admitted to Elazığ Mental Health and Diseases Hospital. The methamphetamine-induced psychotic disorder (MP) with and without lifetime cannabis use (LCU) group will include consecutive participants diagnosed with MP with and without LCU according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). Both groups will consist of active methamphetamine users and will be hospitalized for clinical management at the time of assessment. Urine toxicology screening was performed at admission to confirm substance/drug use status.

Ages

18 to 65 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

1. For Methamphetamine-Induced Psychotic Disorder plus Lifetime Cannabis Use (MP + LCU) Group: \*Inclusion Criteria: • Diagnosis of MP according to DSM-5-TR * Diagnosis of Cannabis Use Disorder according to DSM-5-TR * Medication-free for at least one month prior to admission * Age ≥ 18 years and \<65 years * Provided informed consent For Methamphetamine-Induced Psychotic Disorder plus Lifetime Cannabis Use (MP + LCU) Group: \*Exclusion Criteria: • Hypertension • Diabetes mellitus • Chronic kidney disease • Rheumatoid arthritis • Systemic lupus erythematosus • Cardiac illness * Severe neurological disorders * Immunological or systemic illness * Primary psychiatric disorders other than MP * Alcohol use disorder 2. For Methamphetamine-Induced Psychotic Disorder (MP without LCU) Group: \*Inclusion Criteria: • Diagnosis of MP according to DSM-5-TR • Medication-free for at least one month prior to admission • Age ≥ 18 years and \<65 years • Provided informed consent For Methamphetamine-Induced Psychotic Disorder (MP without LCU) Group: \*Exclusion Criteria: • Hypertension • Diabetes mellitus • Chronic kidney disease * Rheumatoid arthritis * Systemic lupus erythematosus * Cardiac illness * Severe neurological disorders * Immunological or systemic illness * Primary psychiatric disorders other than MP * Alcohol use disorder

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cannabis use are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cannabis dependence methamphetamine-induced psychosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cannabis use Methamphetamine induced psychosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Elazığ Mental Health and Diseases Hospital

    NOT_YET_RECRUITING

    Elâzığ, Elâzığ, 23200, Turkey (Türkiye)

  • Elazığ Mental Health and Diseases Hospital

    RECRUITING

    Elâzığ, Elâzığ, 23200, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.